Table 2 Distribution of studies that reported progression criteria
Variable | Number (%); 95% CI* |
|---|---|
Overall | 45 (19.8); 14.8–25.6 |
Journal | |
 PAFS** | 9 (20.0); 9.6–34.6 |
 BMJ Open*** | 16 (35.6); 21.9–51.2 |
 Trials | 20 (44.4); 29.6–60.0 |
Year of publication | |
 2013 | 4 (8.9); 2.5–21.2 |
 2014 | 3 (6.7); 1.3–18.3 |
 2015 | 5 (11.1); 3.7–24.1 |
 2016 | 19 (42.2); 27.6–57.8 |
 2017 | 14 (31.1); 18.2–46.7 |
Region | |
 North America | 21 (46.7); 31.6–62.13 |
 Europe | 21 (46.7); 31.6–62.13 |
 Other | 3 (6.7); 1.3–18.3 |
Funding | |
 Industry | 12 (28.6); 14.6–41.9 |
 Government or private | 30 (71.4); 51.1–80.0 |
Intervention type | |
 Pharmacological | 7 (15.6); 6.5–29.5 |
 Non-pharmacological | 37 (82.2); 67.9–92.0 |
Feasibility outcomes (yes) | 29 (64.4); 48.8–78.13 |
Sample size reported (yes) | 45 (100); 92.13–100.00 |
Sample size | |
 Small (n = 0–60) | 29 (64.4); 48.8–78.1 |
 Large (n > 60) | 16 (35.6); 21.9–51.2 |
Sample size justification | |
 Adequate | 28 (62.2); 46.5–76.2 |
 Inadequate | 17 (37.8); 23.7–53.5 |